Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma	Multiple Myeloma in Relapse	Active, not recruiting	Phase 2	2026-10-02		NCT04925193

3 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Karyopharm Therapeutics Inc	25
National Cancer Institute (NCI)	3015
University of Colorado, Denver	475

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
University Of Colorado Hospital	Aurora	United States	106

Clinical trials